LV12768B - Metode imūnās reakcijas nomākšanai pret terapeitiskām olbaltumvielām - Google Patents
Metode imūnās reakcijas nomākšanai pret terapeitiskām olbaltumvielām Download PDFInfo
- Publication number
- LV12768B LV12768B LVP-01-62A LV010062A LV12768B LV 12768 B LV12768 B LV 12768B LV 010062 A LV010062 A LV 010062A LV 12768 B LV12768 B LV 12768B
- Authority
- LV
- Latvia
- Prior art keywords
- agent
- composition
- soluble form
- antibody
- hemostatic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (35)
- IZGUDROJUMA FORMULA1. Kompozīcija, saturoša pirmo aģentu, kas stimulē hemostāzi un otro aģentu, kas inhibē kostimulējošo signālu T šūnā.
- 2. Kompozīcija saskaņā ar 1. punktu, kas papildus satur farmaceitiski pieņemamu nesēju.
- 3. Kompozīcija saskaņā ar 1. punktu, kur pirmais aģents ir faktors VIII.
- 4. Kompozīcija saskaņā ar 1. punktu, kur pirmais aģents ir faktora VIII variants ar B-domēna delēciju.
- 5. Kompozīcija saskaņā ar 1. punktu, kur pirmais aģents ir faktors IX.
- 6. Kompozīcija saskaņā ar 1. punktu, kur pirmais aģents ir von Villebranda (Von Willebrand) faktors.
- 7. Kompozīcija saskaņā ar 1. punktu, kur otrais aģents ir kostimulējošās molekulas šķīstošā forma.
- 8. Kompozīcija saskaņā ar 7. punktu, kur otrais aģents ir CTLA4 šķīstošā forma.
- 9. Kompozīcija saskaņā ar 7. punktu, kur otrais aģents ir B7-1 šķīstošā forma, B7-2 šķīstošā forma vai minētās B7-1 šķīstošās formas un minētās B7-21 } šķīstošās formas kombinācija.
- 10. Kompozīcija saskaņā ar 8. punktu, kur otrais aģents ir CTLA4lg.
- 11. Kompozīcija saskaņā ar 7. punktu, kur otrais aģents ir B7-1 Ig vai B7-2lg.
- 12. Kompozīcija saskaņā ar 1. punktu, kur otrais aģents ir CD40 vai CD40L šķīstošā forma.
- 13. Kompozīcija saskaņā ar 1. punktu, kur otrais aģents ir antiviela, kas saistās pie kostimulējošās molekulas.
- 14. Kompozīcija saskaņā ar 13. punktu, kur otrais aģents ir izvēlēts no grupas, kura sastāv no antivielas anti-B7-1, antivielas anti-B7-2 un no antivielas anti-B7-1 un antivielas anti-B7-2 kombinācijas.
- 15. Kompozīcija saskaņā ar 13. punktu, kur antiviela ir antivielas anti-CD28 neaktivējošā forma.
- 16. Kompozīcijas izmantošana saskaņā ar jebkuru no 1. punkta līdz 15. punktam medikamenta pagatavošanai hemostatisku traucējumu ārstēšanai cilvēkam.
- 17. Izmantošana saskaņā ar 16. punktu, kur cilvēkam ir iepriekš eksistējoša imūnā reakcija uz pirmo aģentu.
- 18. Izmantošana saskaņā ar 16. punktu, kur cilvēkam nav iepriekš eksistējošas imūnās reakcijas uz pirmo aģentu.
- 19. Izmantošana saskaņā ar 16. punktu, kur kompozīcija satur papildus imunosupresīvu aģentu.
- 20. Izmantošana saskaņā ar 16. punktu, kur hemostatiskais traucējums ir izvēlēts no grupas, kurā ietilpst hemofīlija A, hemofīlija B, un von Villebranda (Von Willebrand) slimība.
- 21. Kompozīcijas izmantošana medikamenta pagatavošanai hemostatisku traucējumu ārstēšanai cilvēkam, pie kam kompozīcija satur pirmo hemostāzi stimulējošo aģentu un otro aģentu, kas inhibē kostimulējošo signālu T šūnā, tādus, lai tiek novērsts hemostatiskais traucējums.
- 22. Kompozīcijas izmantošana medikamenta pagatavošanai hemostatisku traucējumu ārstēšanai cilvēkam, pie kam kompozīcija satur pirmo hemostāzi stimulējošo aģentu un otro aģentu, kas inhibē kostimulējošo signālu T šūnā, tādus, lai tiek nomākta imūnā reakcija pret pirmo aģentu, līdz ar to ārstējot hemostatisko traucējumu.
- 23. Izmantošana saskaņā ar 21. vai 22. punktu, kur pirmais aģents ir faktors VIII.
- 24. Izmantošana saskaņā ar 21. vai 22. punktu, kur pirmais aģents ir faktora VIII variants ar B-domēna delēciju.
- 25. Izmantošana saskaņā ar 21. vai 22. punktu, kur pirmais aģents ir faktors IX.
- 26. Izmantošana saskaņā ar 21. vai 22. punktu, kur pirmais aģents ir von Villebranda (Von Willebrand) faktors.
- 27. Izmantošana saskaņā ar 21. vai 22. punktu, kur otrais aģents ir aģenta, kas T šūnai nodod kostimulējošo signālu, šķīstošā forma.
- 28. Izmantošana saskaņā ar 27. punktu, kur aģents ir CTLA4 šķīstošā forma.
- 29. Izmantošana saskaņā ar 28. punktu, kur aģents ir CTLA4lg.
- 30. Izmantošana saskaņā ar 27. punktu, kur aģents ir B7-1 šķīstošā forma, B72 šķīstošā forma vai B7-1 šķīstošās formas un B7-2 šķīstošās formas kombinācija.
- 31. Izmantošana saskaņā ar 30. punktu, kur aģents ir B7-1 Ig, B7-2lg vai abu B7-1 Ig un B7-2Ig kombinācija.
- 32. Izmantošana saskaņā ar 21. vai 22. punktu, kur otrais aģents ir antiviela, kas saistās pie kostimulējošās molekulas.
- 33. Izmantošana saskaņā ar 32. punktu, kur otrais aģents ir izvēlēts no grupas, kura sastāv no antivielas anti-B7-1, antivielas anti-B7-2 un no antivielu antiB7-1 un anti-B7-2 kombinācijas.
- 34. Izmantošana saskaņā ar 32. punktu, kur antiviela ir antivielas anti-CD28 neaktivējošā forma.
- 35. Izmantošana saskaņā ar 21. vai 22. punktu, kur hemostatiskais traucējums ir izvēlēts no grupas, kurā ietilpst hemofīlija A, hemofīlija B, un von Villebranda (Von Willebrand) slimība.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15817898A | 1998-09-21 | 1998-09-21 | |
| PCT/US1999/021991 WO2000016801A1 (en) | 1998-09-21 | 1999-09-21 | Methods of downmodulating the immune response to therapeutic proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV12768A LV12768A (lv) | 2001-12-20 |
| LV12768B true LV12768B (lv) | 2002-06-20 |
Family
ID=22566971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-01-62A LV12768B (lv) | 1998-09-21 | 2001-04-20 | Metode imūnās reakcijas nomākšanai pret terapeitiskām olbaltumvielām |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1115423A1 (lv) |
| JP (1) | JP2002526455A (lv) |
| KR (1) | KR20010085830A (lv) |
| CN (1) | CN1331602A (lv) |
| AU (1) | AU761206B2 (lv) |
| BR (1) | BR9913991A (lv) |
| CA (1) | CA2343916A1 (lv) |
| CZ (1) | CZ20011021A3 (lv) |
| EA (1) | EA005236B1 (lv) |
| HK (1) | HK1039059A1 (lv) |
| HU (1) | HUP0103960A3 (lv) |
| IL (1) | IL142069A0 (lv) |
| LT (1) | LT4920B (lv) |
| LV (1) | LV12768B (lv) |
| MX (1) | MXPA01002898A (lv) |
| NO (1) | NO20011412L (lv) |
| NZ (1) | NZ511034A (lv) |
| PL (1) | PL346796A1 (lv) |
| SI (1) | SI20626A (lv) |
| WO (1) | WO2000016801A1 (lv) |
| ZA (1) | ZA200103156B (lv) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| JP2003534291A (ja) * | 2000-05-19 | 2003-11-18 | ザ センター フォー ブラッド リサーチ インク | Ｐ−セレクチン活性の変調による止血障害の診断及び治療方法 |
| WO2005010483A2 (en) * | 2003-06-10 | 2005-02-03 | Smiths Detection Inc. | Sensor arrangement |
| GB201508024D0 (en) * | 2015-05-11 | 2015-06-24 | Haemostatix Ltd | Haemostatic compositions |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171569A (en) | 1985-03-15 | 1992-12-15 | National Research Development Corporation | Factor IX preparations uncontaminated by plasma components or pox virus |
| US4868112A (en) | 1985-04-12 | 1989-09-19 | Genetics Institute, Inc. | Novel procoagulant proteins |
| US5422260A (en) | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
| US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
| FR2657884B1 (fr) | 1990-02-05 | 1994-09-02 | Tm Innovation | Procede pour la preparation du facteur viii humain et d'analogues du facteur viii. |
| US5661008A (en) | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
| US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| CA2110518C (en) | 1991-06-27 | 2007-05-22 | Peter S. Linsley | Ctla4 receptor, fusion proteins containing it and uses thereof |
| WO1993009804A1 (en) | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation |
| US5744446A (en) | 1992-04-07 | 1998-04-28 | Emory University | Hybrid human/animal factor VIII |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US5663060A (en) | 1992-04-07 | 1997-09-02 | Emory University | Hybrid human/animal factor VIII |
| US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| WO1996005860A1 (en) * | 1994-08-19 | 1996-02-29 | Novo Nordisk A/S | A method of treating a patient with a biologically active compound |
| CA2200869A1 (en) * | 1994-10-19 | 1996-05-02 | Bruce C. Trapnell | Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents |
| US5714583A (en) | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
| JP4751493B2 (ja) * | 1996-03-20 | 2011-08-17 | ブリストル−マイヤーズ スクイッブ カンパニー | Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物 |
| ATE356634T1 (de) * | 1997-01-10 | 2007-04-15 | Biogen Idec Inc | Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln |
| AU733062B2 (en) * | 1997-06-20 | 2001-05-03 | Biogen Idec Ma Inc. | CD154 blockade therapy for therapeutic protein inhibitor syndrome |
| US8112896B2 (en) | 2009-11-06 | 2012-02-14 | Hexagon Metrology Ab | Articulated arm |
-
1999
- 1999-09-21 JP JP2000573762A patent/JP2002526455A/ja not_active Withdrawn
- 1999-09-21 CN CN99813510A patent/CN1331602A/zh active Pending
- 1999-09-21 CZ CZ20011021A patent/CZ20011021A3/cs unknown
- 1999-09-21 PL PL99346796A patent/PL346796A1/xx not_active Application Discontinuation
- 1999-09-21 MX MXPA01002898A patent/MXPA01002898A/es unknown
- 1999-09-21 EA EA200100385A patent/EA005236B1/ru not_active IP Right Cessation
- 1999-09-21 IL IL14206999A patent/IL142069A0/xx unknown
- 1999-09-21 HK HK02100157.7A patent/HK1039059A1/zh unknown
- 1999-09-21 CA CA002343916A patent/CA2343916A1/en not_active Abandoned
- 1999-09-21 AU AU60578/99A patent/AU761206B2/en not_active Ceased
- 1999-09-21 WO PCT/US1999/021991 patent/WO2000016801A1/en not_active Ceased
- 1999-09-21 BR BR9913991-0A patent/BR9913991A/pt not_active IP Right Cessation
- 1999-09-21 HU HU0103960A patent/HUP0103960A3/hu unknown
- 1999-09-21 KR KR1020017003611A patent/KR20010085830A/ko not_active Withdrawn
- 1999-09-21 EP EP99969339A patent/EP1115423A1/en not_active Withdrawn
- 1999-09-21 NZ NZ511034A patent/NZ511034A/xx unknown
- 1999-09-21 SI SI9920084A patent/SI20626A/sl not_active IP Right Cessation
-
2001
- 2001-03-20 NO NO20011412A patent/NO20011412L/no not_active Application Discontinuation
- 2001-04-18 ZA ZA200103156A patent/ZA200103156B/xx unknown
- 2001-04-20 LT LT2001045A patent/LT4920B/lt not_active IP Right Cessation
- 2001-04-20 LV LVP-01-62A patent/LV12768B/lv unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU6057899A (en) | 2000-04-10 |
| BR9913991A (pt) | 2001-07-03 |
| NO20011412D0 (no) | 2001-03-20 |
| CA2343916A1 (en) | 2000-03-30 |
| LT4920B (lt) | 2002-06-25 |
| HUP0103960A2 (hu) | 2002-02-28 |
| PL346796A1 (en) | 2002-02-25 |
| AU761206B2 (en) | 2003-05-29 |
| WO2000016801A9 (en) | 2000-10-26 |
| KR20010085830A (ko) | 2001-09-07 |
| CZ20011021A3 (cs) | 2001-10-17 |
| JP2002526455A (ja) | 2002-08-20 |
| HUP0103960A3 (en) | 2003-09-29 |
| EP1115423A1 (en) | 2001-07-18 |
| EA005236B1 (ru) | 2004-12-30 |
| NO20011412L (no) | 2001-05-16 |
| LT2001045A (en) | 2002-01-25 |
| SI20626A (sl) | 2002-02-28 |
| IL142069A0 (en) | 2002-03-10 |
| LV12768A (lv) | 2001-12-20 |
| MXPA01002898A (es) | 2002-06-04 |
| EA200100385A1 (ru) | 2001-10-22 |
| NZ511034A (en) | 2004-03-26 |
| WO2000016801A1 (en) | 2000-03-30 |
| CN1331602A (zh) | 2002-01-16 |
| ZA200103156B (en) | 2002-07-18 |
| HK1039059A1 (zh) | 2002-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alon et al. | TNF-alpha binds to the N-terminal domain of fibronectin and augments the beta 1-integrin-mediated adhesion of CD4+ T lymphocytes to the glycoprotein. | |
| White II et al. | A multicenter study of recombinant factor VIII (RecombinateTM) in previously treated patients with hemophilia A | |
| Bidanset et al. | Binding of the proteoglycan decorin to collagen type VI. | |
| ES2136618T5 (es) | Curacion de heridas. | |
| CA2246352A1 (en) | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith | |
| GEP20043161B (en) | Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators | |
| TR199902194T2 (xx) | +p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler. | |
| FR2714378B1 (fr) | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. | |
| EP1806364A3 (fr) | Nouveaux anticorps anti-igf-ir et leurs applications | |
| GEP20033131B (en) | Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity | |
| CA2221730A1 (en) | Use of angiotensin ii type 2 receptor agonists in tissue repair | |
| NZ332995A (en) | A protein which binds to osteoclastogenesis inhibitory factor (OCIF) | |
| DE69435171D1 (de) | Pan dr-bindeproteinen zur erhöhung der immunantwort | |
| DE60141043D1 (de) | Rekombinante anti-cd30-antikörper und deren verwendungen | |
| ATE324907T1 (de) | Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen | |
| CA2247247A1 (en) | Troponin subunits and fragments useful as angiogenesis inhibitors | |
| FI972703A0 (fi) | Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia | |
| BR9811094A (pt) | Agente terapêutico para tumores linfáticos | |
| CA2378613A1 (en) | Selective iglur5 receptor antagonists for the treatment of migraine | |
| CA2343579A1 (en) | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists | |
| DE59406938D1 (de) | Pharmazeutische zubereitungen mit einem wirkstoff, der modifizierte amidingruppen enthält | |
| PL340465A1 (en) | Antibodies against phosphorylated vasp (vasodilating agent stimulated phosphoprotein) hybridom cells for obtaining them and their application | |
| ATE269865T1 (de) | Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren | |
| CA2233138A1 (en) | Inhibitors of integrin receptors and their therapeutical uses | |
| LV12768B (lv) | Metode imūnās reakcijas nomākšanai pret terapeitiskām olbaltumvielām |